Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with SBRT in Pancreatic Cancer
NCT02311361Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2015
- Primary completion
- Oct 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tremelimumab in pancreatic cancer (PC), sponsored by National Cancer Institute. Started Mar 2015; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02311361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02311361.